[go: up one dir, main page]

GT201300036A - Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos - Google Patents

Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Info

Publication number
GT201300036A
GT201300036A GT201300036A GT201300036A GT201300036A GT 201300036 A GT201300036 A GT 201300036A GT 201300036 A GT201300036 A GT 201300036A GT 201300036 A GT201300036 A GT 201300036A GT 201300036 A GT201300036 A GT 201300036A
Authority
GT
Guatemala
Prior art keywords
n3pglu
amiloide
peptidic
same
beta
Prior art date
Application number
GT201300036A
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Demattos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201300036A publication Critical patent/GT201300036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS QUE SELECTIVAMENTE UNEN PÉPTIDO BETA AMILOIDE N3PGLU Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADA A PÉPTIDO BETA AMILOIDE POR LO QUE SON DE UTILIDAD EN UN NÚMERO DE CONDICIONES Y ENFERMEDADES, QUE INCLUYEN LA ENFERMEDAD DE ALZHEIMER, ANGIOPATÍA AMILOIDE CEREBRAL
GT201300036A 2010-08-12 2013-02-08 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos GT201300036A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
GT201300036A true GT201300036A (es) 2014-07-16

Family

ID=44543826

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300036A GT201300036A (es) 2010-08-12 2013-02-08 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Country Status (38)

Country Link
US (2) US8679498B2 (es)
EP (3) EP2603523B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN105111308B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK2603523T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2764728T3 (es)
GT (1) GT201300036A (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE037524T2 (es)
IL (2) IL224030B (es)
LT (2) LT3042917T (es)
MA (1) MA34461B1 (es)
ME (3) ME02352B (es)
MX (2) MX342782B (es)
MY (2) MY163521A (es)
NO (1) NO3042917T3 (es)
NZ (2) NZ626665A (es)
PE (1) PE20130817A1 (es)
PH (1) PH12013500277A1 (es)
PL (3) PL2603523T3 (es)
PT (2) PT3042917T (es)
RS (3) RS54685B1 (es)
SG (2) SG187586A1 (es)
SI (3) SI3339323T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
LT3042917T (lt) * 2010-08-12 2018-05-10 Eli Lilly And Company Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
CN106604932B (zh) 2014-07-10 2024-12-10 苏黎世大学 人白细胞介素-2的免疫刺激单克隆抗体
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3234611A1 (en) 2014-12-19 2017-10-25 Probiodrug AG Novel method for the detection of pglu-abeta peptides
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
CN108290951B (zh) * 2015-09-23 2022-04-01 瑞泽恩制药公司 优化抗cd3双特异性抗体和其用途
BR112018014150A2 (en) 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740944A (zh) * 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
AR107774A1 (es) 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
WO2018034977A1 (en) 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
SI3672631T1 (sl) 2017-08-22 2023-06-30 Biogen Ma Inc. Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
CN111465410B (zh) 2017-12-14 2022-10-25 H.隆德贝克有限公司 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン
CN110366560B (zh) * 2018-02-11 2023-07-28 江苏豪森药业集团有限公司 抗b7-h4抗体、其抗原结合片段及其医药用途
AU2019233603B2 (en) * 2018-03-13 2025-06-26 Smivet B.V. Single domain antibodies binding to tetanus neurotoxin
WO2020193644A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
WO2021257808A2 (en) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
AU2021355518A1 (en) * 2020-10-02 2023-06-08 Eli Lilly And Company Methods for reducing host cell protein content in protein purification processes
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
CA3235104A1 (en) * 2021-10-22 2023-04-27 Kevin BIGLAN O-glcnacase (oga) inhibitor combination therapy
TW202336034A (zh) 2021-10-29 2023-09-16 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
CN118475609A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
KR20240099347A (ko) 2021-10-29 2024-06-28 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
EP4472679A1 (en) 2022-02-03 2024-12-11 Eli Lilly and Company Regional tau imaging for diagnosing and treating alzheimer's disease
CR20250023A (es) 2022-07-21 2025-02-17 Lilly Co Eli SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3pGlu Aß Y USOS DE ESTAS
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
AU2005217596B2 (en) * 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
WO2009149487A2 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
JP2011527338A (ja) 2008-07-09 2011-10-27 ユニバーシティー オブ チューリッヒ 神経新生を促進する方法
JP5828762B2 (ja) * 2008-07-21 2015-12-09 プロビオドルグ エージー 診断用抗体アッセイ
EP2576617B1 (en) 2010-06-04 2016-04-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
LT3042917T (lt) * 2010-08-12 2018-05-10 Eli Lilly And Company Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas

Also Published As

Publication number Publication date
LT3042917T (lt) 2018-05-10
CN103068848B (zh) 2015-11-25
EP3339323A1 (en) 2018-06-27
IL285226B2 (en) 2023-02-01
MX355268B (es) 2018-04-11
PT3042917T (pt) 2018-05-02
NZ606095A (en) 2014-11-28
ECSP13012436A (es) 2013-03-28
HRP20160151T1 (hr) 2016-03-11
CN105111308A (zh) 2015-12-02
CN103068848A (zh) 2013-04-24
ME03661B (me) 2020-07-20
WO2012021469A1 (en) 2012-02-16
HK1180703A1 (zh) 2013-10-25
JP2013536191A (ja) 2013-09-19
ES2564252T3 (es) 2016-03-21
RS57026B1 (sr) 2018-05-31
BR112013004056B1 (pt) 2022-05-17
CL2013000390A1 (es) 2014-03-21
SG10201509330XA (en) 2015-12-30
PL3042917T3 (pl) 2018-07-31
PL2603523T3 (pl) 2016-07-29
AU2011289629B2 (en) 2014-07-03
MX2013001716A (es) 2013-10-28
PT3339323T (pt) 2020-01-14
BR112013004056A2 (pt) 2020-08-04
MA34461B1 (fr) 2013-08-01
ZA201300437B (en) 2014-06-25
EP3042917B1 (en) 2018-02-21
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
IL285226A (en) 2021-09-30
EP3339323B1 (en) 2019-11-13
EA201270813A1 (ru) 2013-05-30
ES2664128T3 (es) 2018-04-18
LT3339323T (lt) 2020-02-10
RS54685B1 (sr) 2016-08-31
SI3339323T1 (sl) 2019-12-31
US8679498B2 (en) 2014-03-25
CY1122458T1 (el) 2021-01-27
US20140065138A1 (en) 2014-03-06
DK2603523T3 (en) 2016-03-21
CR20130016A (es) 2013-03-21
EP2603523A1 (en) 2013-06-19
HRP20180616T1 (hr) 2018-07-13
PH12013500277A1 (en) 2017-04-21
CA2805114C (en) 2017-12-05
IL224030B (en) 2022-04-01
ME03032B (me) 2018-10-20
CY1120144T1 (el) 2018-12-12
UA107600C2 (uk) 2015-01-26
SI2603523T1 (sl) 2016-04-29
MX342782B (es) 2016-10-12
MY163521A (en) 2017-09-15
US20130142806A1 (en) 2013-06-06
MY181969A (en) 2021-01-15
BR112013004056B8 (pt) 2022-10-18
US8961972B2 (en) 2015-02-24
CN105111308B (zh) 2019-03-12
NO3042917T3 (es) 2018-07-21
CO6670526A2 (es) 2013-05-15
JP5980207B2 (ja) 2016-08-31
SI3042917T1 (en) 2018-04-30
PE20130817A1 (es) 2013-07-18
EP3042917A1 (en) 2016-07-13
EP2603523B1 (en) 2016-01-27
ME02352B (me) 2016-06-20
JP6395755B2 (ja) 2018-09-26
CA2805114A1 (en) 2012-02-16
EA023021B1 (ru) 2016-04-29
DOP2013000029A (es) 2013-03-15
NZ626665A (en) 2016-04-29
DK3339323T3 (da) 2020-01-20
KR20130051989A (ko) 2013-05-21
JP2016179985A (ja) 2016-10-13
AU2011289629A1 (en) 2013-02-14
HUE028678T2 (en) 2016-12-28
PL3339323T3 (pl) 2020-05-18
DK3042917T3 (en) 2018-04-23
HUE037524T2 (hu) 2018-09-28
ES2764728T3 (es) 2020-06-04
HRP20192233T1 (hr) 2020-03-06
IL285226B (en) 2022-10-01
RS59652B1 (sr) 2020-01-31

Similar Documents

Publication Publication Date Title
GT201300036A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
AR132544A2 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
UY33202A (es) Proteínas de unión a cd127
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
CL2021000088A1 (es) Anticuerpos anti-cd27 (divisional de solicitud 779-2019).
GT201700033A (es) Anticuerpos anti tigit
MX371496B (es) Anticuerpos y ensayos para la detección del receptor 1 de folato.
CY1122987T1 (el) Αντισωματα εναντι αμυλοειδους βητα
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
CU20160101A7 (es) Inmunoglobulina con fab en tándem
SV2017005486A (es) Anticuerpos a tau y usos de los mismos
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
ECSP13012609A (es) Composición farmacéutica
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
PL3468997T3 (pl) Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
UY33850A (es) Anticuerpos anti ? cd38
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
EP3590542C0 (en) POSITRON-EMITTING RADIONUCLEID-LABELED PEPTIDES FOR HUMAN POSITRON EMISSION TOMOGRAPHY (PET) IMAGING
MX2014013678A (es) Agentes para neutralizacion de influenza.
IL229858B (en) Polypeptides and uses thereof for tratment of autoimmune disorders and infection
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso